세포 및 유전자 치료 제조 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Cell and Gene Therapy Manufacturing Market - Scope of Report

TMR's report on the global cell and gene therapy manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing market. Key players operating in the global cell and gene therapy manufacturing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Market Report:

• What is the sales/revenue generated by cell and gene therapy manufacturing across all regions during the forecast period?
• What are the opportunities in the global cell and gene therapy manufacturing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cell and Gene Therapy Manufacturing Market - Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Cell and Gene Therapy Manufacturing Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Technological Advancements
• 5.2. Reimbursement Scenario by Region/Globally
• 5.3. Regulatory Scenario by Region/globally
• 5.4. Disease Prevalence & Incidence Rate Globally With Key Countries
• 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Therapy Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Therapy Type, 2017-2031
  • 6.3.1. Cell Therapy
    • 6.3.1.1. Allogeneic
      • 6.3.1.1.1. Mesenchymal Stem Cells
      • 6.3.1.1.2. T-cells
      • 6.3.1.1.3. Induced Pluripotent Stem Cells
      • 6.3.1.1.4. Natural Killer Cells
      • 6.3.1.1.5. Hematopoietic Stem Cells
      • 6.3.1.1.6. Others
    • 6.3.1.2. Autologous
      • 6.3.1.2.1. T-cells
      • 6.3.1.2.2. Hematopoietic Stem Cells
      • 6.3.1.2.3. Mesenchymal Stem Cells
      • 6.3.1.2.4. Natural Killer Cells
      • 6.3.1.2.5. Others
  • 6.3.2. Gene Therapy
    • 6.3.2.1. Viral Vector
      • 6.3.2.1.1. Lentiviral Vector
      • 6.3.2.1.2. Adeno-associated Virus Vectors
      • 6.3.2.1.3. Other Viral Vectors
    • 6.3.2.2. Non-viral Vector
      • 6.3.2.2.1. Electroporation
      • 6.3.2.2.2. Other Non-viral Vectors
• 6.4. Market Attractiveness Analysis, by Therapy Type

7. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Product Type

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Product Type, 2017-2031
  • 7.3.1. Consumables
  • 7.3.2. Equipment
    • 7.3.2.1. Cell Processing Equipment
    • 7.3.2.2. Single-use Equipment
    • 7.3.2.3. Other Equipment
  • 7.3.3. Software & Systems
• 7.4. Market Attractiveness Analysis, by Product Type

8. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Technology

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Technology, 2017-2031
  • 8.3.1. Cell Culture & Expansion
  • 8.3.2. Viral Vector Production
  • 8.3.3. Cell Sorting & Purification
  • 8.3.4. Gene Editing
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis, by Technology

9. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Indication

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Indication, 2017-2031
  • 9.3.1. Oncology Disease
  • 9.3.2. Cardiovascular Disease
  • 9.3.3. Orthopedic Disease
  • 9.3.4. Infectious Disease
  • 9.3.5. Others
• 9.4. Market Attractiveness Analysis, by Indication

10. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by End-user

• 10.1. Introduction & Definition
• 10.2. Key Findings/Developments
• 10.3. Market Value Forecast, by End-user, 2017-2031
  • 10.3.1. Pharmaceutical & Biotechnology Companies
  • 10.3.2. Contract Manufacturing Organizations (CMOs)
• 10.4. Market Attractiveness Analysis, by End-user

11. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Region

• 11.1. Key Findings
• 11.2. Market Value Forecast, by Region, 2017-2031
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness Analysis, by Region

12. North America Cell and Gene Therapy Manufacturing Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Therapy Type, 2017-2031
  • 12.2.1. Cell Therapy
    • 12.2.1.1. Allogeneic
      • 12.2.1.1.1. Mesenchymal Stem Cells
      • 12.2.1.1.2. T-cells
      • 12.2.1.1.3. Induced Pluripotent Stem Cells
      • 12.2.1.1.4. Natural Killer Cells
      • 12.2.1.1.5. Hematopoietic Stem Cells
      • 12.2.1.1.6. Others
    • 12.2.1.2. Autologous
      • 12.2.1.2.1. T-cells
      • 12.2.1.2.2. Hematopoietic Stem Cells
      • 12.2.1.2.3. Mesenchymal Stem Cells
      • 12.2.1.2.4. Natural Killer Cells
      • 12.2.1.2.5. Others
  • 12.2.2. Gene Therapy
    • 12.2.2.1. Viral Vector
      • 12.2.2.1.1. Lentiviral Vector
      • 12.2.2.1.2. Adeno-associated Virus Vectors
      • 12.2.2.1.3. Other Viral Vectors
    • 12.2.2.2. Non-viral Vector
      • 12.2.2.2.1. Electroporation
      • 12.2.2.2.2. Other Non-viral Vectors
• 12.3. Market Value Forecast, by Product Type, 2017-2031
  • 12.3.1. Consumables
  • 12.3.2. Equipment
    • 12.3.2.1. Cell Processing Equipment
    • 12.3.2.2. Single-use Equipment
    • 12.3.2.3. Other Equipment
  • 12.3.3. Software & Systems
• 12.4. Market Value Forecast, by Technology, 2017-2031
  • 12.4.1. Cell Culture & Expansion
  • 12.4.2. Viral Vector Production
  • 12.4.3. Cell Sorting & Purification
  • 12.4.4. Gene Editing
  • 12.4.5. Others
• 12.5. Market Value Forecast, by Indication, 2017-2031
  • 12.5.1. Oncology Disease
  • 12.5.2. Cardiovascular Disease
  • 12.5.3. Orthopedic Disease
  • 12.5.4. Infectious Disease
  • 12.5.5. Others
• 12.6. Market Value Forecast, by End-user, 2017-2031
  • 12.6.1. Pharmaceutical & Biotechnology Companies
  • 12.6.2. Contract Manufacturing Organizations (CMOs)
• 12.7. Market Value Forecast, by Country, 2017-2031
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Therapy Type
  • 12.8.2. By Product Type
  • 12.8.3. By Technology
  • 12.8.4. By Indication
  • 12.8.5. By End-user
  • 12.8.6. By Country

13. Europe Cell and Gene Therapy Manufacturing Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Therapy Type, 2017-2031
  • 13.2.1. Cell Therapy
    • 13.2.1.1. Allogeneic
      • 13.2.1.1.1. Mesenchymal Stem Cells
      • 13.2.1.1.2. T-cells
      • 13.2.1.1.3. Induced Pluripotent Stem Cells
      • 13.2.1.1.4. Natural Killer Cells
      • 13.2.1.1.5. Hematopoietic Stem Cells
      • 13.2.1.1.6. Others
    • 13.2.1.2. Autologous
      • 13.2.1.2.1. T-cells
      • 13.2.1.2.2. Hematopoietic Stem Cells
      • 13.2.1.2.3. Mesenchymal Stem Cells
      • 13.2.1.2.4. Natural Killer Cells
      • 13.2.1.2.5. Others
  • 13.2.2. Gene Therapy
    • 13.2.2.1. Viral Vector
      • 13.2.2.1.1. Lentiviral Vector
      • 13.2.2.1.2. Adeno-associated Virus Vectors
      • 13.2.2.1.3. Other Viral Vectors
    • 13.2.2.2. Non-viral Vector
      • 13.2.2.2.1. Electroporation
      • 13.2.2.2.2. Other Non-viral Vectors
• 13.3. Market Value Forecast, by Product Type, 2017-2031
  • 13.3.1. Consumables
  • 13.3.2. Equipment
    • 13.3.2.1. Cell Processing Equipment
    • 13.3.2.2. Single-use Equipment
    • 13.3.2.3. Other Equipment
  • 13.3.3. Software & Systems
• 13.4. Market Value Forecast, by Technology, 2017-2031
  • 13.4.1. Cell Culture & Expansion
  • 13.4.2. Viral Vector Production
  • 13.4.3. Cell Sorting & Purification
  • 13.4.4. Gene Editing
  • 13.4.5. Others
• 13.5. Market Value Forecast, by Indication, 2017-2031
  • 13.5.1. Oncology Disease
  • 13.5.2. Cardiovascular Disease
  • 13.5.3. Orthopedic Disease
  • 13.5.4. Infectious Disease
  • 13.5.5. Others
• 13.6. Market Value Forecast, by End-user, 2017-2031
  • 13.6.1. Pharmaceutical & Biotechnology Companies
  • 13.6.2. Contract Manufacturing Organizations (CMOs)
• 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.7.1. Germany
  • 13.7.2. U.K.
  • 13.7.3. France
  • 13.7.4. Italy
  • 13.7.5. Spain
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Therapy Type
  • 13.8.2. By Product Type
  • 13.8.3. By Technology
  • 13.8.4. By Indication
  • 13.8.5. By End-user
  • 13.8.6. By Country/Sub-region

14. Asia Pacific Cell and Gene Therapy Manufacturing Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Therapy Type, 2017-2031
  • 14.2.1. Cell Therapy
    • 14.2.1.1. Allogeneic
      • 14.2.1.1.1. Mesenchymal Stem Cells
      • 14.2.1.1.2. T-cells
      • 14.2.1.1.3. Induced Pluripotent Stem Cells
      • 14.2.1.1.4. Natural Killer Cells
      • 14.2.1.1.5. Hematopoietic Stem Cells
      • 14.2.1.1.6. Others
    • 14.2.1.2. Autologous
      • 14.2.1.2.1. T-cells
      • 14.2.1.2.2. Hematopoietic Stem Cells
      • 14.2.1.2.3. Mesenchymal Stem Cells
      • 14.2.1.2.4. Natural Killer Cells
      • 14.2.1.2.5. Others
  • 14.2.2. Gene Therapy
    • 14.2.2.1. Viral Vector
      • 14.2.2.1.1. Lentiviral Vector
      • 14.2.2.1.2. Adeno-associated Virus Vectors
      • 14.2.2.1.3. Other Viral Vectors
    • 14.2.2.2. Non-viral Vector
      • 14.2.2.2.1. Electroporation
      • 14.2.2.2.2. Other Non-viral Vectors
• 14.3. Market Value Forecast, by Product Type, 2017-2031
  • 14.3.1. Consumables
  • 14.3.2. Equipment
    • 14.3.2.1. Cell Processing Equipment
    • 14.3.2.2. Single-use Equipment
    • 14.3.2.3. Other Equipment
  • 14.3.3. Software & Systems
• 14.4. Market Value Forecast, by Technology, 2017-2031
  • 14.4.1. Cell Culture & Expansion
  • 14.4.2. Viral Vector Production
  • 14.4.3. Cell Sorting & Purification
  • 14.4.4. Gene Editing
  • 14.4.5. Others
• 14.5. Market Value Forecast, by Indication, 2017-2031
  • 14.5.1. Oncology Disease
  • 14.5.2. Cardiovascular Disease
  • 14.5.3. Orthopedic Disease
  • 14.5.4. Infectious Disease
  • 14.5.5. Others
• 14.6. Market Value Forecast, by End-user, 2017-2031
  • 14.6.1. Pharmaceutical & Biotechnology Companies
  • 14.6.2. Contract Manufacturing Organizations (CMOs)
• 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Therapy Type
  • 14.8.2. By Product Type
  • 14.8.3. By Technology
  • 14.8.4. By Indication
  • 14.8.5. By End-user
  • 14.8.6. By Country/Sub-region

15. Latin America Cell and Gene Therapy Manufacturing Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Therapy Type, 2017-2031
  • 15.2.1. Cell Therapy
    • 15.2.1.1. Allogeneic
      • 15.2.1.1.1. Mesenchymal Stem Cells
      • 15.2.1.1.2. T-cells
      • 15.2.1.1.3. Induced Pluripotent Stem Cells
      • 15.2.1.1.4. Natural Killer Cells
      • 15.2.1.1.5. Hematopoietic Stem Cells
      • 15.2.1.1.6. Others
    • 15.2.1.2. Autologous
      • 15.2.1.2.1. T-cells
      • 15.2.1.2.2. Hematopoietic Stem Cells
      • 15.2.1.2.3. Mesenchymal Stem Cells
      • 15.2.1.2.4. Natural Killer Cells
      • 15.2.1.2.5. Others
  • 15.2.2. Gene Therapy
    • 15.2.2.1. Viral Vector
      • 15.2.2.1.1. Lentiviral Vector
      • 15.2.2.1.2. Adeno-associated Virus Vectors
      • 15.2.2.1.3. Other Viral Vectors
    • 15.2.2.2. Non-viral Vector
      • 15.2.2.2.1. Electroporation
      • 15.2.2.2.2. Other Non-viral Vectors
• 15.3. Market Value Forecast, by Product Type, 2017-2031
  • 15.3.1. Consumables
  • 15.3.2. Equipment
    • 15.3.2.1. Cell Processing Equipment
    • 15.3.2.2. Single-use Equipment
    • 15.3.2.3. Other Equipment
  • 15.3.3. Software & Systems
• 15.4. Market Value Forecast, by Technology, 2017-2031
  • 15.4.1. Cell Culture & Expansion
  • 15.4.2. Viral Vector Production
  • 15.4.3. Cell Sorting & Purification
  • 15.4.4. Gene Editing
  • 15.4.5. Others
• 15.5. Market Value Forecast, by Indication, 2017-2031
  • 15.5.1. Oncology Disease
  • 15.5.2. Cardiovascular Disease
  • 15.5.3. Orthopedic Disease
  • 15.5.4. Infectious Disease
  • 15.5.5. Others
• 15.6. Market Value Forecast, by End-user, 2017-2031
  • 15.6.1. Pharmaceutical & Biotechnology Companies
  • 15.6.2. Contract Manufacturing Organizations (CMOs)
• 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Therapy Type
  • 15.8.2. By Product Type
  • 15.8.3. By Technology
  • 15.8.4. By Indication
  • 15.8.5. By End-user
  • 15.8.6. By Country/Sub-region

16. Middle East & Africa Cell and Gene Therapy Manufacturing Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast, by Therapy Type, 2017-2031
  • 16.2.1. Cell Therapy
    • 16.2.1.1. Allogeneic
      • 16.2.1.1.1. Mesenchymal Stem Cells
      • 16.2.1.1.2. T-cells
      • 16.2.1.1.3. Induced Pluripotent Stem Cells
      • 16.2.1.1.4. Natural Killer Cells
      • 16.2.1.1.5. Hematopoietic Stem Cells
      • 16.2.1.1.6. Others
    • 16.2.1.2. Autologous
      • 16.2.1.2.1. T-cells
      • 16.2.1.2.2. Hematopoietic Stem Cells
      • 16.2.1.2.3. Mesenchymal Stem Cells
      • 16.2.1.2.4. Natural Killer Cells
      • 16.2.1.2.5. Others
  • 16.2.2. Gene Therapy
    • 16.2.2.1. Viral Vector
      • 16.2.2.1.1. Lentiviral Vector
      • 16.2.2.1.2. Adeno-associated Virus Vectors
      • 16.2.2.1.3. Other Viral Vectors
    • 16.2.2.2. Non-viral Vector
      • 16.2.2.2.1. Electroporation
      • 16.2.2.2.2. Other Non-viral Vectors
• 16.3. Market Value Forecast, by Product Type, 2017-2031
  • 16.3.1. Consumables
  • 16.3.2. Equipment
    • 16.3.2.1. Cell Processing Equipment
    • 16.3.2.2. Single-use Equipment
    • 16.3.2.3. Other Equipment
  • 16.3.3. Software & Systems
• 16.4. Market Value Forecast, by Technology, 2017-2031
  • 16.4.1. Cell Culture & Expansion
  • 16.4.2. Viral Vector Production
  • 16.4.3. Cell Sorting & Purification
  • 16.4.4. Gene Editing
  • 16.4.5. Others
• 16.5. Market Value Forecast, by Indication, 2017-2031
  • 16.5.1. Oncology Disease
  • 16.5.2. Cardiovascular Disease
  • 16.5.3. Orthopedic Disease
  • 16.5.4. Infectious Disease
  • 16.5.5. Others
• 16.6. Market Value Forecast, by End-user, 2017-2031
  • 16.6.1. Pharmaceutical & Biotechnology Companies
  • 16.6.2. Contract Manufacturing Organizations (CMOs)
• 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Therapy Type
  • 16.8.2. By Product Type
  • 16.8.3. By Technology
  • 16.8.4. By Indication
  • 16.8.5. By End-user
  • 16.8.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 17.2. Market Share Analysis, by Company (2022)
• 17.3. Company Profiles
  • 17.3.1. Becton, Dickinson and Company
    • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.1.2. Product Portfolio
    • 17.3.1.3. Financial Overview
    • 17.3.1.4. SWOT Analysis
    • 17.3.1.5. Strategic Overview
  • 17.3.2. Bio-Rad Laboratories, Inc.
    • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.2.2. Product Portfolio
    • 17.3.2.3. Financial Overview
    • 17.3.2.4. SWOT Analysis
    • 17.3.2.5. Strategic Overview
  • 17.3.3. Bio-Techne Corporation
    • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.3.2. Product Portfolio
    • 17.3.3.3. Financial Overview
    • 17.3.3.4. SWOT Analysis
    • 17.3.3.5. Strategic Overview
  • 17.3.4. Danaher Corporation
    • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.4.2. Product Portfolio
    • 17.3.4.3. Financial Overview
    • 17.3.4.4. SWOT Analysis
    • 17.3.4.5. Strategic Overview
  • 17.3.5. General Electric Company (GE Healthcare)
    • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.5.2. Product Portfolio
    • 17.3.5.3. Financial Overview
    • 17.3.5.4. SWOT Analysis
    • 17.3.5.5. Strategic Overview
  • 17.3.6. Getinge AB
    • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.6.2. Product Portfolio
    • 17.3.6.3. Financial Overview
    • 17.3.6.4. SWOT Analysis
    • 17.3.6.5. Strategic Overview
  • 17.3.7. Lonza Group Ltd.
    • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.7.2. Product Portfolio
    • 17.3.7.3. Financial Overview
    • 17.3.7.4. SWOT Analysis
    • 17.3.7.5. Strategic Overview
  • 17.3.8. Merck KGaA
    • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.8.2. Product Portfolio
    • 17.3.8.3. Financial Overview
    • 17.3.8.4. SWOT Analysis
    • 17.3.8.5. Strategic Overview
  • 17.3.9. Sartorius AG (Sartorius Stedim Biotech S.A.)
    • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.9.2. Product Portfolio
    • 17.3.9.3. Financial Overview
    • 17.3.9.4. SWOT Analysis
    • 17.3.9.5. Strategic Overview
  • 17.3.10. Thermo Fisher Scientific Inc.
    • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.10.2. Product Portfolio
    • 17.3.10.3. Financial Overview
    • 17.3.10.4. SWOT Analysis
    • 17.3.10.5. Strategic Overview
  • 17.3.11. MaxCyte
    • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.11.2. Product Portfolio
    • 17.3.11.3. Financial Overview
    • 17.3.11.4. SWOT Analysis
    • 17.3.11.5. Strategic Overview
  • 17.3.12. Fresenius Medical Care AG & Co. KGaA
    • 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 17.3.12.2. Product Portfolio
    • 17.3.12.3. Financial Overview
    • 17.3.12.4. SWOT Analysis
    • 17.3.12.5. Strategic Overview